# A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

> **NCT07709715** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nexcella Inc.** · enrollment: 260 (estimated)

## Conditions studied

- Light Chain (AL) Amyloidosis

## Interventions

- **BIOLOGICAL:** NXC-201
- **DRUG:** Dara-CyBorD

## Key facts

- **NCT ID:** NCT07709715
- **Lead sponsor:** Nexcella Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2028-12
- **Final completion:** 2032-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709715, "A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*